Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

Comparison of four basic models of indirect pharmacodynamic responses

Natalie Dayneka, Varun Garg, William J. Jusko · Journal of Pharmacokinetics and Biopharmaceutics · 1993 · 811 citations

Medicine, Pharmacokinetics, Pharmacology +14

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 274 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

Chiaki Tanaka, Terence O’Reilly, John M. Kovarik et al. · Journal of Clinical Oncology · 2008 · 210 citations

Medicine, Pharmacokinetics, Pharmacology +17

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

L. Buéno, Dinesh P. de Alwis, Celine Pitou et al. · European Journal of Cancer · 2007 · 202 citations

Medicine, Oncology, Pharmacology +15